Cause-effect relationship between the hepatitis C virus and insulin resistance at the time of direct antiviral therapy
| Autor: | Negro Francesco, Covolo Loredana, Pasino Michela, Perini Eleonora, Rossi Luigi, Brocco Giorgio, Guido Maria, Cristofori Chiara, Belotti Caterina, Puoti Massimo, Gaeta Giovanni Battista, Santantonio Teresa, Raimondo Giovanni, Bruno Raffaele, Minola Eliseo, Donato Francesco, Italian Hepatitis C Cohort Study Collaborative Group |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Hepatitis C
Chronic/drug therapy/*physiopathology Cirrhosis Hepatitis C virus Hepacivirus Carbohydrate metabolism medicine.disease_cause Antiviral Agents 03 medical and health sciences Liver disease chemistry.chemical_compound 0302 clinical medicine Insulin resistance medicine Humans 030304 developmental biology ddc:616 0303 health sciences biology business.industry Hepacivirus/drug effects/physiology Ribavirin Gastroenterology Hepatitis C Chronic medicine.disease biology.organism_classification 3. Good health Antiviral Agents/*therapeutic use chemistry Insulin Resistance/*physiology Immunology 030211 gastroenterology & hepatology Metabolic syndrome Insulin Resistance business |
| Zdroj: | Gut Gut, Vol. 59, No 12 (2010) pp. 1590-1591 |
| ISSN: | 1468-3288 0017-5749 |
| Popis: | Hepatitis C virus (HCV) is a major cause of progressive liver damage, infecting an estimated 3% of the world population. Morbidity and mortality associated with chronic hepatitis C are mainly attributable to progression towards cirrhosis and its end-stage complications. Thus, the main goal of treatment is the prevention of liver disease progression, an objective that can be attained via the eradication of HCV infection with antiviral therapy. The current standard of care consists of a combination of pegylated interferon α (IFNα) and ribavirin, with a cure rate of about 55%. Novel effective direct antiviral agents (DAA), targeting specific viral functions, are expected to be commercially available towards the end of 2011, raising hopes of significant improvements in the cure rates. An important aspect of HCV infection is its idiosyncratic relationship with the metabolism of glucose,1 which negatively affects liver disease progression and the response to IFNα-based therapies1 while also raising the possibility of multifaceted and clinically relevant interactions with the metabolic syndrome. Although many viral infections induce insulin resistance, the effect of HCV on glucose metabolism is remarkable and supported by a large amount of clinical, epidemiological and experimental data.1 Changes in glucose metabolism are more significant in patients … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|